October 27, 2020 -- ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.
The early discovery collaboration will expand on Talem's diverse antibody pipeline by exploring ImmunoPrecise's technology in a wide range of oncology targets. ImmunoPrecise will contribute targets and the genetic sequences for lead antibodies against the selected targets. Twist Biopharma, a division of Twist Bioscience, will design synthetic antibody libraries based on the provided antibody repertoire sequences from immunized animals to discover optimized, humanized lead antibody candidates.
The companies aim to jointly advance the programs through proof-of-concept and preclinical development and will collaborate on any commercial opportunities generated by the efforts that may result in milestones or key preclinical, clinical, and commercial milestones as well as royalties for any antibodies resulting from the collaboration.